Impact of meningococcal C conjugate vaccine on incidence of invasive meningococcal disease in an 18‐year time‐series in Brazil and in distinct Brazilian regions

2022 ◽  
Author(s):  
Mariana C. Cruz ◽  
Paulo Camargos ◽  
Cristiana M. Nascimento‐Carvalho
Keyword(s):  
Time Series ◽  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Invasive Meningococcal Disease

scholarly journals Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine

2013 ◽  
Vol 66 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Wiebke Hellenbrand ◽  
Johannes Elias ◽  
Ole Wichmann ◽  
Manuel Dehnert ◽  
Matthias Frosch ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Invasive Meningococcal Disease

Invasive Meningococcal Disease in Africa’s Meningitis Belt: More Than Just Meningitis?

2019 ◽  
Vol 220 (Supplement_4) ◽  
pp. S263-S265 ◽  
Author(s):  
Heather E Reese ◽  
Olivier Ronveaux ◽  
Jason M Mwenda ◽  
Andre Bita ◽  
Adam L Cohen ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Disease Surveillance ◽  
Clinical Presentation ◽  
Case Fatality ◽  
Clinical Syndrome ◽  
Invasive Meningococcal Disease ◽  
World Health ◽  
Case Fatality Ratio ◽  
Meningitis Belt

Abstract Since the progressive introduction of the meningococcal serogroup A conjugate vaccine within Africa’s meningitis belt beginning in 2010, the burden of meningitis due to Neisseria meningitidis serogroup A (NmA) has substantially decreased. Non-A serogroups C/W/X are now the most prevalent. Surveillance within the belt has historically focused on the clinical syndrome of meningitis, the classic presentation for NmA, and may not adequately capture other presentations of invasive meningococcal disease (IMD). The clinical presentation of infection due to serogroups C/W/X includes nonmeningeal IMD, and there is a higher case-fatality ratio associated with these non-A serogroups; however, data on the nonmeningeal IMD burden within the belt are scarce. Expanding surveillance to capture all cases of IMD, in accordance with the World Health Organization’s updated vaccine-preventable disease surveillance standards and in preparation for the anticipated introduction of a multivalent meningococcal conjugate vaccine within Africa’s meningitis belt, will enhance meningococcal disease prevention across the belt.

scholarly journals Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy

Vaccine ◽  
2018 ◽  
Vol 36 (29) ◽  
pp. 4222-4227 ◽  
Author(s):  
Patrizio Pezzotti ◽  
Alessandro Miglietta ◽  
Arianna Neri ◽  
Cecilia Fazio ◽  
Paola Vacca ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Vaccine Effectiveness ◽  
Invasive Meningococcal Disease

scholarly journals Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection

2009 ◽  
Vol 20 (4) ◽  
pp. e130-e134 ◽  
Author(s):  
Nicole Le Saux ◽  
Julie A Bettinger ◽  
Susan Wootton ◽  
Scott A Halperin ◽  
Wendy Vaudry ◽  
...  
Keyword(s):  
New Brunswick ◽  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Prince Edward Island ◽  
Value Added ◽  
Invasive Meningococcal Disease ◽  
Immunization Programs ◽  
Meningococcal Infections ◽  
Conjugate Vaccines ◽  
Routine Infant

Canada is a leader in establishing routine infant immunization programs against meningococcal C disease. Currently, all provinces have routine programs to provide meningococcal C conjugate vaccines to infants and children. The result of the existing programs has been a decrease in serogroup C incidence. The second most common vaccine-preventable serogroup in Canada is serogroup Y, the incidence of which has been stable. The availability of a quadrivalent conjugate vaccine against serogroups A, C, Y and W135 focuses attention on serogroup Y disease as it becomes relatively more prominent as a cause of vaccine-preventable invasive meningococcal disease. This vaccine was licensed in November 2006 but is not routinely used except in Nunavut, New Brunswick and Prince Edward Island. To allow a better understanding of the ‘value added’ by a serogroup Y-containing vaccine, it is necessary to have a contemporary profile of Y disease in Canada. In the present paper, recent surveillance data on invasive meningococcal disease across Canada are summarized.

Sign in / Sign up

Export Citation Format

Share Document